Gabrielle B. Fredman, Ph.D.
Affiliations: | 2009 | Boston University, Boston, MA, United States |
Area:
DentistryGoogle:
"Gabrielle Fredman"Parents
Sign in to add mentorThomas E. Van Dyke | grad student | 2009 | Boston University | |
(Resolvin E1 regulation of platelet functions: Novel pathways in resolution.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Fredman G, Serhan CN. (2024) Specialized pro-resolving mediators in vascular inflammation and atherosclerotic cardiovascular disease. Nature Reviews. Cardiology |
Fredman G, Khan S. (2023) Specialized pro-resolving mediators enhance the clearance of dead cells. Immunological Reviews. 319: 151-157 |
Spite M, Fredman G. (2023) Insights into the role of the resolvin D2-GPR18 signaling axis in cardiovascular physiology and disease. Advances in Pharmacology (San Diego, Calif.). 97: 257-281 |
Grazda R, Seyfried AN, Maddipatti KR, et al. (2023) Impaired inflammation resolution in murine bone marrow failure is rescued by Resolvin E1 treatment. Biorxiv : the Preprint Server For Biology |
Fredman G, MacNamara KC. (2022) Atherosclerosis is a major human killer and non-resolving inflammation is a prime suspect. Cardiovascular Research. 117: 2563-2574 |
Decker C, Sadhu S, Fredman G. (2021) Pro-Resolving Ligands Orchestrate Phagocytosis. Frontiers in Immunology. 12: 660865 |
Gerlach BD, Marinello M, Heinz J, et al. (2019) Resolvin D1 promotes the targeting and clearance of necroptotic cells. Cell Death and Differentiation |
Fredman G. (2019) Can Inflammation-Resolution Provide Clues to Treat Patients According to Their Plaque Phenotype? Frontiers in Pharmacology. 10: 205 |
Yurdagul A, Doran AC, Cai B, et al. (2017) Mechanisms and Consequences of Defective Efferocytosis in Atherosclerosis. Frontiers in Cardiovascular Medicine. 4: 86 |
Fredman G, Tabas I. (2017) Boosting Inflammation Resolution in Atherosclerosis: The Next Frontier for Therapy. The American Journal of Pathology. 187: 1211-1221 |